Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsHow do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesSummary of emerging personalized medicine in neuroendocrine tumors: are we on track?Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives.Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?Management of the hormonal syndrome of neuroendocrine tumors.Update in the Therapy of Advanced Neuroendocrine Tumors.Chemotherapy in Pancreatic Cancer: A Systematic Review
P2860
Q26740374-8F3045FB-251F-474C-8BFA-52563CD5F6C6Q26750748-4BFDE955-03EE-4C73-862A-9F83C80E2AEFQ28078610-59FFBF4F-1349-41E0-BA5A-1096CB0CDD6AQ36184629-505C1386-C78F-49C3-96FF-7A0E8302A4F6Q38730927-D8684B36-7080-42B5-8877-64015CC4EE15Q38842250-2CADA694-CE9D-4CF1-93BF-8F199FA28030Q38955246-DB3DCB52-A78F-40C1-8C91-5B6B865C4D74Q39201601-FF01F6CC-2C7C-4123-A8AE-08AC68371106Q39848776-E74E347F-11EC-4832-8068-8365A479D0EFQ41832570-10F6DBFE-F5FD-4117-A14C-E894F873B756Q49970741-C327459D-08E0-4FB4-8004-EFDE9C1CC730Q57824846-949B1AD6-77E1-42BC-8E85-CDB724A653CC
P2860
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@ast
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@en
type
label
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@ast
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@en
prefLabel
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@ast
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@en
P2093
P2860
P1433
P1476
Impact of prior chemotherapy u ...... the phase III RADIANT-3 trial.
@en
P2093
Ashok Panneerselvam
Catherine Lombard-Bohas
Edward M Wolin
James C Yao
Jaume Capdevila
Manisha H Shah
Rodney Pommier
Sotirios Stergiopoulos
Timothy Hobday
P2860
P304
P356
10.1097/MPA.0000000000000262
P577
2015-03-01T00:00:00Z